Lisa Anne Carey, MD, talks with Otto Metzger, MD, about the results of the phase 3 PATINA trial, which evaluated the efficacy and safety of palbociclib + anti-HER2 therapy + endocrine therapy vs. anti-HER2 therapy after induction treatment for hormone receptor-positive (HR+)/HER-positive metastatic breast cancer.
▷ Estimated Read Time:
1–2 minutes
SABCS Snippets: Results from the AFT-38 PATINA trial
Join the global breast cancer community for four days of research spanning experimental biology, etiology, translational science, prevention, diagnosis and treatment, December 8-11 in San Antonio, Texas.
Share: